HB Wealth Management LLC Purchases Shares of 9,351 GSK plc (NYSE:GSK)

HB Wealth Management LLC purchased a new position in shares of GSK plc (NYSE:GSK) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 9,351 shares of the pharmaceutical company’s stock, valued at approximately $316,000.

Several other large investors also recently bought and sold shares of the company. Eastern Bank purchased a new position in shares of GSK during the 3rd quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its holdings in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners boosted its holdings in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new position in GSK during the third quarter valued at about $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 1.9 %

Shares of NYSE GSK opened at $34.08 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $70.63 billion, a PE ratio of 22.13, a price-to-earnings-growth ratio of 1.32 and a beta of 0.63. The firm’s 50-day moving average is $33.89 and its 200-day moving average is $37.87. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.61%. GSK’s dividend payout ratio (DPR) is presently 96.10%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several analyst reports. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.